As of November 6, 2026, LeonaBio, Inc. is a publicly traded company (Nasdaq: LONA). The largest holder reporting an active stake on Schedule 13D is Sermonix Pharmaceuticals, Inc., at 25.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Anders Hove (12.1%), ADAR1 Capital (7.7%), Great Point Partners, LLC (5.03%) (Schedule 13D/A, October 28, 2026).
Is this your company?
About to sign with, pay or invest in LeonaBio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is LeonaBio, Inc. a real, registered company?
- LeonaBio, Inc. files with the SEC under CIK 1620463 (its SEC filings).
- Its shares are listed under the ticker LONA on Nasdaq (SEC company record).
- business address in Bothell, Washington, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under LeonaBio, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Great Point Partners, LLC (filed 2026-11-04).
Who are LeonaBio, Inc.'s owners and officers?
LeonaBio, Inc.: business address in Bothell, Washington; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-11-04).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-11-04 | Great Point Partners, LLC | 5.03% |
| Schedule 13D/A, 2026-10-28 | Sermonix Pharmaceuticals, Inc. | 25.1% |
| Schedule 13D/A, 2026-10-26 | Perceptive Advisors LLC | 19.99% |
| Schedule 13D, 2026-08-31 | Sermonix Pharmaceuticals, Inc. | 36.9% |
| Schedule 13D/A, 2026-08-25 | Perceptive Advisors LLC | 19.99% |
| Schedule 13G/A, 2026-08-20 | Anders Hove | 12.1% |
| Schedule 13G, 2026-05-15 | Adar1 Capital Management, LLC | 7.7% |
| Schedule 13D/A, 2026-05-07 | Perceptive Advisors LLC | 19.99% |
| Schedule 13G/A, 2026-02-06 | Baselake Partners, LP | 1.9% |
| Schedule 13D/A, 2026-01-16 | Perceptive Advisors LLC | 19.99% |
| Schedule 13G/A, 2026-01-08 | Anders Hove | 6.2% |
| Schedule 13G, 2025-12-23 | Anders Hove | 5.2% |
Questions about who owns LeonaBio, Inc.
Who owns LeonaBio, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of LeonaBio, Inc.: Sermonix Pharmaceuticals, Inc. (25.1%, Schedule 13D/A, filed 2026-10-28), Perceptive Advisors LLC (19.99%, Schedule 13D/A, filed 2026-10-26), Anders Hove (12.1%, Schedule 13G/A, filed 2026-08-20), Adar1 Capital Management, LLC (7.7%, Schedule 13G, filed 2026-05-15) and Great Point Partners, LLC (5.03%, Schedule 13G, filed 2026-11-04).
Who are the largest shareholders of LeonaBio, Inc.?
By the share each holder's latest filing reports, the largest holders of LeonaBio, Inc. on this page are Sermonix Pharmaceuticals, Inc. (25.1%), Perceptive Advisors LLC (19.99%) and Anders Hove (12.1%).
When did Sermonix Pharmaceuticals, Inc. buy into LeonaBio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sermonix Pharmaceuticals, Inc. on this page is the Schedule 13D, filed 2026-08-31, reporting 36.9%; its latest, Schedule 13D/A filed 2026-10-28, reports 25.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on LeonaBio, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on LeonaBio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on LeonaBio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own LeonaBio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a 10% owner: 3,149,470 shares (33.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes) (Form 4, 2026-10-28).
- Perceptive Advisors, a director and 10% owner: 776,648 shares (8.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-26).
- , a director and 10% owner: 776,648 shares (8.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-26).
- Perceptive Life Sciences Master Fund Ltd., a director and 10% owner: 776,648 shares (8.2% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-10-26).
- Perceptive Xontogeny Venture Fund II, LP, a director and 10% owner: 329,756 shares (3.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-12-23).
Shares outstanding: 9,421,663 as of 2026-08-04, from the company's latest SEC cover page.
How much has LeonaBio, Inc. raised?
Latest IPO step: LeonaBio, Inc. amended its IPO registration (S-1/A, 2026-03-31).
IPO filings: S-1/A, 2026-03-31, S-1/A, 2026-03-31; ticker LONA on Nasdaq Capital Market.
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-03-31).
Keep reading
More on LeonaBio, Inc. and the records around it.
LeonaBio, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Oliveira Steven Michael also filed stake reports on 1 other company: Forte Biosciences, Inc. (Jan 2026)
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), enGene Therapeutics Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Baselake Partners, LP also filed stake reports on 7 other companies: KIORA PHARMACEUTICALS, INC. (Sep 2026), Passage Bio, Inc. (Jun 2026), Generation Bio Co. (Feb 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/leonabio